NIH Aranesp study
National Cancer Institute study to identify equivalent doses of Aranesp and J&J's Procrit should not be necessary for CMS to revise its reimbursement decision on Amgen's anemia agent, company tells analysts April 22. Amgen, CMS have been involved in "a dense set of discussions...looking at large amounts of clinical data," CEO Kevin Sharer says. "We don't expect...that any trial run by another part of the government will be necessary to come to the right conclusion and...I don't think, at this point...that [CMS sees] that as necessary either," Sharer says. CMS contracted the NCI study when it decided Aranesp should be reimbursed at the same rate as Procrit (1"The Pink Sheet" Nov. 4, 2002, p. 27)...
You may also be interested in...
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.